Professor Kate Moore

W.R. Pitney Clinical Sciences Building – Private Rooms

LOCATION:
Level 1, W.R. Pitney Clinical Sciences Building
St George Hospital
Short Street, KOGARAH  NSW  2217
Telephone:  (02) 9113 2054
Facsimile:  (02) 9113 3951

OFFICE HOURS:
Monday – Friday  9.00am – 5.00pm

(02) 9113 2272
Mon - Fri: 9:00AM - 5:00PM
Title Image

Research

Home  /  Research

Peer Reviewed Publications

  1. Moore KH, Hay D, Imrie A, Watson A, Goldstein M. Oxybutynin Hydrochloride 3mg in the treatment of women with idiopathic detrusor instability.  Brit J Urol 1990; 66: 479-485
  2. Moore KH, Sutherst JR. Response to treatment of detrusor instability in relation to psychoneurotic status. Brit J Urol 1990; 66: 486-490
  3. Moore KH, Richmond DH, Sutherst JR. Urinary acidity in relation to detrusor instability. Neurourol & Urodyn 1990; 9: 331-332
  4. Moore KH, Sill PR. Domiciliary fetal monitoring in a district maternity unit. Aust NZ J Obstets & Gynaecol 1990; 30: 36-40
  5. Moore KH, Richmond DH, Sutherst JR, Imrie AI, Hutton JL. Crouching over the toilet seat:  Prevalence among British gynaecological outpatients and its effect upon micturition.  Brit J Obstets & Gynaecol 1991; 98: 569-572
  6. Moore KH, Richmond DH, Parys BT. Sex distribution of adult idiopathic detrusor instability in relation to childhood bedwetting. Brit J Urol 1991; 68: 479-482
  7. Moore KH, Vaillant C, Nameth J, Richmond D, Sutherst J. Vasoactive intestinal polypeptide in refractory detrusor instability.  Neurourol & Urodyn 1991; 10: 330-331
  8. Moore KH, Nickson P, Richmond DH, Sutherst JR, Manasse PR, & Helliwell TR. Detrusor mast cells in refractory idiopathic instability. Brit J Urol 1992; 70: 17-21
  9. Moore KH, Gilpin SA, Dixon JS, Richmond DH & Sutherst JR. Increase of presumptive sensory nerves of the urinary bladder in idiopathic detrusor instability. Brit J Urol 1992; 70: 370-372
  10. Moore KH, Richmond DH, Sutherst JR, Manasse P. Is severe “wetness” associated with severe “madness” in detrusor instability? Neurourol & Urodyn 1992; 11: 460-461
  11. Zeng XP, Moore KH, Burcher E. Characterization of Tachykinin NK-2 receptors in human urinary bladder. J Urol 1995; 153: 1688-1692
  12. Burcher E, Zeng XP, Farnsworth RH, Moore KH. Functional characterization of tachykinin NK-2 receptors in child urinary bladder.  Neurourol & Urodyn 1995; 14: 546-548
  13. Moore KH. Detrusor Instability in Women. Its significance for continence therapists. Invited Review, Brit J Physiotherapy 1996; 82: 52-57
  14. Bower WF, Moore KH, Shepherd RB, Adams R. The epidemiology of childhood enuresis in Australia. Brit J Urol 1996; 78: 602-606
  15. Millard RJ, Moore KH. Urinary incontinence: the Cinderella subject. Invited Editorial.  Med J Aust 1996; 165: 124-125
  16. Bower WF, Moore KH. Frequency volume chart data from 322 incontinent children. Brit J Urol 1997; 80: 658-662
  17. Smet P, Moore KH, Jonavicius J. Distribution and colocalisation of calcitonin gene-related peptide, tachykinins, and vasoactive intestinal peptide in normal and idiopathic unstable human urinary bladder. Lab Invest 1997; 77: 37-49
  18. Moore KH, Foote AJ, Siva S, King J, Burton G. The use of the bladder neck support prosthesis in combined genuine stress incontinence and detrusor instability.   ANZJOG 1997; 37: 440-445
  19. Bower WF, Moore KH, Adams RD, Shepherd RB. A urodynamic study of surface neuromodulation versus sham in detrusor instability and sensory urgency. J Urol 1998; 106: 2133-2136
  20. Moore KH, Foote AJ, Burton G, King J. An open study of the bladder neck support prosthesis in genuine stress incontinence.  Brit J Obstets & Gynaecol 1999; 106: 42-49
  21. Dowell CJ, Bryant CM, Moore KH, Simons AM. Calculation of the direct costs of urinary incontinence: the DBICI, a new test instrument.  Brit J Urol 1999; 83: 596-606
  22. Moore KH. Current controversies in the diagnosis, aetiology and management of detrusor instability. Critical Reviews in Physical and Rehabilitation Medicine. (Invited Review) 1999; 11: 35-61
  23. Millard R, Tuttle J, Moore KH, Susset J, Clarke B, Dwyer P, Davis BE. Clinical efficacy and safety of Tolterodine compared to placebo in detrusor overactivity. J Urol 1999; 161: 1551-1555
  24. Simons A, Cragg S, Moore KH. The sub-optimal accuracy of the bladderscan:.Neurourol & Urodyn 1999; 18: 307-308
  25. Moore KH, Simons A, Dowell C, Bryant C, Prashar S. Efficacy and user acceptability of the urethral occlusive device in women with urinary incontinence. J Urol 1999; 162: 464-468
  26. Burcher E, Strigas J, Zeng XP, Shang F, Millard RJ, Moore KH. Autoradiographic localization of tackykinin and calcitonin gene-related peptide receptors in adult urinary bladder. J Urol 1162: 464-468
  27. Werkstrom V, Lam DSH, Farnsworth RH, Awar N, Burcher E, Moore KH. In vitro contractile responses of detrusor to carbachol and neurokinin A, in children with recurrent urinary tract infection or day wetting.  Brit J Urol 2000; 85: 319-325
  28. Prashar S, Simons A, Bryant C, Dowell C, Moore KH. Attitudes to vaginal/urethral touching and device placement in women with urinary incontinence. Int Urogynaecol J 2000; 11: 4-8
  29. Moore KH, Simons A, Mukerjee C, Lynch W. Relative incidence of detrusor instability and bacterial cystitis found on the urodynamic test day. Brit J Urol 2000; 85: 786-792
  30. Lam DSH, Dias LS, Moore KH, Burcher E. Angiotensin II in child urinary bladder: functional and autoradiographic studies. Brit J Urol 2000; 86: 494-501
  31. Simons AM, Dowell CJ, Bryant CM, Prashar S, Moore KH. outcome Use of the Dowell Bryant incontinence cost index as a post-treatment measure. Neurourol & Urodyn. 2001; 20: 85-93
  32. Simons AM, Yoong WC, Buckland S, Moore KH. Inadequate repeatability of the one hour pad test: need for a new incontinence outcome measure. Brit J Obstets & Gynae 2001; 108: 315-319
  33. Moore KH. The costs of urinary incontinence: human suffering and financial drain. Med J Aust 2001; 174: 436-437 (Invited Review)
  34. Moore KH, Ray F, Barden JA. Loss of purinergic P2X3 and P2X5 receptor innervation in human detrusor from adults with urge incontinence. J Neuroscience 2001; 21: RC166:1-6
  35. Bower WF, Moore KH, Adams RD. A pilot study of the home application of transcutaneous neuromodulation in children with urgency or urge incontinence. J Urol 2001; 166: 2420-2422
  36. Clausen JA, Lynch WJ, Aslan P, Moore KH. Alterations in the distribution of GAP-43/P75NTR in urinary bladder from human urge syndrome/OAB. Neurourol & Urodyn 2001; 20: 399-401
  37. Bower WF, Moore KH, Adams RD. A novel clinical evaluation of childhood incontinence and urinary urgency. J Urol 2001; 166: 2411-2415
  38. Moore KH, Lam DSH, Lynch W, Burcher E. Role of tachykinin NK-2 receptors in non-cholinergic contractility of normal and unstable human urinary bladder. Peptides. 2002; 23: 1155-1160
  39. Moore KH, Louey M, Ip V, Swinfield J, Ho MP. The cost of a continence service in the acute hospital – is it being “counted”? Neurourol & Urodyn 2002; 21: 345-347
  40. Moore KH, Ho MT, Lapsley HM, Green J, Smoker I, Morris A, O’Sullivan R, Louey M, Werda J, Walsh J, Dowell C, Gonski P, Shiaxates C, Poulos C. Development of a framework for economic and cost evaluations for continence conditions. Aust Cont J 2002; 8: 59-62
  41. Dietz HP, Moore KH, Steensma AB. Antenatal pelvic organ mobility is associated with delivery mode.  ANZJOG 2003; 43: 70-74
  42. Herbison P, Hay-Smith J, Ellis G, Moore KH. Effectiveness of anticholinergic drugs compared with placebo in treatment of overactive bladder: systematic review. Brit Med J 2003; 326: 841-847.
  43. Qi JC, Li L, Li Yong, Moore KH, Madigan MC, Katsoulotos G, Krilis SA. An antibody raised against in vitro-derived human mast cells identifies mature mast cells and a population of cells that are Fc&RI+, Tryptase–, and Chymase– in a variety of human tissues. Journal of Histochemistry & Cytochemistry 2003; 51: 643-653
  44. Green P, Smoker I, Ho MT, Moore KH. Urinary incontinence in sub-acute care – a retrospective data analysis. Med. J Aust 2003; 178: 550-553
  45. Karantanis E, O’Sullivan R, Moore KH. The 24-hour pad test in continent women and men: normal values and cyclical alterations. Brit J Obstet & Gynae 2003; 110: 567-571
  46. Blackwell AL, Moore KH. Does detrusor overactivity ever cease? Repeat urodynamic testing at 1 to 9 years. Neurourol & Urodyn 2003; 22: 462-463
  47. Moore KH, O’Sullivan RJ, Simons A, Prashar S, Anderson P, Louey M. Randomized controlled trial of nurse continence advisor therapy versus standard urogynaecology regime for conservative incontinence treatment: Efficacy, costs and two year follow up. Brit.J Obstet & Gynae 2003; 110: 649-657
  48. Mansfield KJ, Mitchelson FJ, Moore KH, Burcher E. Muscarinic receptor subtypes in the human colon: lack of evidence for atypical subtypes. Eur J Pharmacol 2003; 482: 101-109
  49. Ray FR, Moore KH, Hansen MA, Barden JA. Loss of purinergic P2X receptor innervation in human detrusor and subepithelium from adults with sensory urgency. Cell and Tissue Res 2003; 314: 351-359
  50. O’Sullivan R, Simons A, Prashar S, Anderson P, Louey A, Moore KH. Is objective cure of mild undifferentiated incontinence more readily achieved than that of moderate incontinence? Costs and two-year outcome. Int J Urogynaecol. 2003; 14: 193-198
  51. Morris A, Moore KH. The Contiform incontinence device – efficacy and patient acceptability. Int. J Urogynaecol 2003; 14: 412-417. DOI: 10.1007/s00192-021-04969-7
  52. Millard RJ, Moore KH, Rencken, Yalcin I, Bump RC. Duloxetine vs placebo in treatment of stress urinary incontinence: a four continent RCT. Brit J Urol 2004; 93: 11-318
  53. Blackwell AL, Yoong W, Moore KH. Criterion validity, test-retest reliability and sensitivity to change of the St George Urinary Incontinence Score. Brit J Urol 2004; 93: 331-335
  54. Karantanis E, Fynes M, Moore KH, Stanton SL. Comparison of the ICIQ-SF and 24-hour pad test with other measures for evaluating the severity of urodynamic stress incontinence. Int.Urogynecol J 2004; 15: 111-116
  55. 54. Deans CL, Morris AR, O’Sullivan R, Moore KH. Voiding difficulty and other adverse events after tension free vaginal tape. Aust NZ Cont J. 2004; 10: 34-41
  56. Morris AR, Mullan G, Roscioli T, Buckley MF, Moore KH. A genetic linkage study of detrusor
  57. O’Sullivan R, Karantanis E, Stevermuer TL, Allen W, Moore KH. Definition of mild, moderate overactivity. Neurourol & Urodyn 2004; 23: 404-406 and severe incontinence on the 24-hour pad test. Brit J Obstet & Gynae 2004; 111: 859-862.
  58. Moore KH. Duloxetine: a new approach for treating stress urinary incontinence. Int J Gynecol Obstet 86 Suppl 1 2004, S53-S62 (Invited Review)
  59. Moore KH. Pelvic Floor Dysfunction: how best to treat? (Invited Review) RANZCOG Obs Gynae. 2004; 6: 195-196
  60. Morris A, Ho MT, Walsh J, Gonski G, Lapsley H, Moore KH. Costs of managing urinary and faecal incontinence in a subacute care facility. A “bottom up” approach. Neurourol Urodyn 2005; 24: 56-62
  61. Karantanis E, Allen W, Stevermuer TL, Simons AM, O’Sullivan R, Moore KH. The repeatability of the 24-hour pad test. Int Urogynecol J 2005; 16: 63-68
  62. Mansfield KJ, Liu L, Mitchelson FJ, Moore KH, Burcher E. Muscarinic receptor subtypes in human bladder detrusor and mucosa, studied by radioligand binding and quantitative competitive RT-PCR: changes in ageing. Brit J Pharmacol 2005; 144: 1089-1099. doi: 10.1038/sj.bjp.0706147
  63. Schofield EC, Clausen JA, Burcher E, Moore KH. GAP-43 immunoreactivity in subepithelial and detrusor muscle nerve fibres in females with refractory idiopathic detrusor overactivity. Neurourol Urodyn. 2005; 24: 325-333
  64. Kuteesa W, Moore KH. Anticholinergic drugs for overactive bladder. (Invited review) Australian Prescriber 2006; 29: 22-24 DOI: 10.18773/austprescr.2006.012
  65. Sadananda P, Lazzaro VA, Moore KH, Burcher E, Mansfield KJ. Urothelial cells isolated from urine of female subjects release ATP in response to acid. Neurourol Urodyn. 2006; 25: 559-560
  66. Woodman, JR. Moore KH, Thornton M, Burns H, King D. Anal incontinence after transanal versus transvaginal repair of rectocoele: matched pair cohort analysis. ANZ Cont J 2007;13: 40-45
  67. Mansfield KJ, Liu L, Moore KH, Vaux KJ, Millard RJ, Burcher E. Molecular characterization of M2 and M3 muscarinic receptor expression in bladder from women with refractory idiopathic detrusor overactivity. BJU Int. 2007; 99: 1433-1438. DOI: 10.1111/j.1464-410X.2007.06866.x
  68. Chua WC, Liu L, Mansfield KJ, Vaux KJ, Moore KH, Millard RJ, Burcher E. Age-related changes of P2X1 receptor mrna in the bladder detrusor from men with and without bladder outlet obstruction. Experimental Gerontology 2007; 42: 686-692. DOI: 10.1016/j.exger.2007.02.003
  69. Foote AJ, Moore KH. The cost of urogynaecological treatments: which are more cost effective? ANZJOG 2007; 47: 240-246. DOI: 10.1111/j.1479-828X.2007.00726.x
  70. Morris A, O’Sullivan R, Dunkley P, Moore KH. Extracorporeal magnetic stimulation in female detrusor overactivity; simultaneous cystometry testing and a randomized sham controlled trial. European Urology 2007, 52: 876-883. DOI: 10.1016/j.eururo.2007.02.026
  71. Steers WD, Herschorn S, Kreder KJ, Moore KH, Strohbehn K, Yalcin I, Bump RC for the Duloxetine OAB Study Group. Duloxetine compared with placebo for treating women with symptoms of overactive bladder. Brit J Urol Int 2007; 100: 337-345. DOI: 10.1111/j.1464-410X.2007.06980.x
  72. Moore KH, Sarma S. The changing face of detrusor overactivity therapy in Australia (invited review). ANZ Cont J, 2007; 13: 90-94  Invited Review.
  73. Morris AR, Westbrook JI, Moore KH. A longitudinal study over 5 to 10 years of clinical outcomes in women with idiopathic detrusor overactivity. Brit J Obs & Gynae 2007; 115: 239-246. DOI: 10.1111/j.1471-0528.2007.01527.x
  74. Allen WA, Leek H, Izurieta A, Moore KH. Update: the “Contiform” intravaginal device in four sizes for treatment of stress incontinence. Int J Urogynaecol. 2008; 19: 757-761. DOI: 10.1007/s00192-007-0519-1
  75. Sarma S, Thakkar K, Hayes W, Karantanis E, Hawthorn G, Moore KH. The development of an Incontinence Treatment Motivation Questionnaire for patients undergoing pelvic floor physiotherapy in the treatment of stress incontinence.  Int. J Urogynaecol. 2009; 20: 1085-1093. DOI: 10.1007/s00192-009-0907-9
  76. Sarma S, Ying, T, Moore KH. Long term vaginal ring pessary use:  discontinuation rates and adverse events.  Brit J Obstet & Gynae 2009; 116: 1715 -21. DOI: 10.1111/j.1471- 0528.2009.02380.x
  77. Moore KH. Is the current ‘definition’ of bacterial cystitis appropriate for women with coexistent lower urinary tract symptoms (LUTS)?  ANZ Cont J. 2009; 15: 4: 124-125 Invited Review
  78. Sarma S, Hersch M, Siva S, Dietz H, Moore KH. Women who cannot contract their pelvic floor muscles – avulsion or denervation?  Neurology & Urodyn, 2009; 28: 680-681
  79. Walsh CA, Moore KH, Recurrent stress urinary incontinence after synthetic midurethral sling procedure.  Obstet & Gynae 2010; 115: 1296- 301. DOI: 10.1097/AOG.0b013e3181da3a48
  80. Walsh CA, Allen W, Moore KH. ‘Urinary incontinence’ post-radiotherapy:  A diagnostic conundrum.  Obstet & Gynae, 2010; 30: 424-5. DOI: 10.3109/01443611003725464
  81. Nitti VW, Kopp Z, Lin ATL, Moore KH, Oefelein M, Mills W. ‘Can we predict which patient will fail drug treatment for overactive bladder?  A think tank discussion.’ Neurourol. Urodyn, 2010;   29: 652-657. DOI: 10.1002/nau.20910
  82. Birder LA, Kanai AJ, Cruz F, Moore KH, Fry CH. ‘Is the Urothelium Intelligent?’  Neurourol. Urodyn. 2010; 29: 598-602. DOI: 10.1002/nau.20914
  83. Abrahams P, Anderson KE, Birder L, Brunaker L, Cardozo L, Chapple A, Cottenden A, Davila W, de Ridder D, Dmochowski R, Drake M, DuBeau C, Fry C, Hanno P, Hay Smith J, Herschorn S, Hosker G, Kelleher C, Koelbl H, Khoury S, Madoff R, Milsom I, Moore KH, et al Evaluation and treatment of Urinary Incontinence, Pelvic Organ Prolapse, and Fecal Incontinence. Neurourol. Urodyn, 2010;   29: 213-240
  84. Cheng Y, Mansfield KJ, Allen W, Walsh CA, Burcher E, Moore KH, Does Adenosine triphosphate (ATP) release into cystometric bladder washings contribute to the signalling of urgency in women with bladder dysfunction? J Urol 2010, 183; 3:1082-6. DOI: 10.1016/j.juro.2009.11.028
  85. Woodman JR, Mansfield KJ, Lazzaro VA, Lynch W, Burcher E, Moore KH, Immunocytochemical characterisation of cultures of human bladder mucosal cells. BMC Urology, 2011; 11: 5-30
  86. Walsh CA, Moore KH. Overactive bladder in women: does low-count bacteriuria matter?  Neurol Urodyn.  2011; 30: 32-37  Invited Review.  DOI: 10.1002/nau.20927
  87. Cheng Y, Mansfield KJ, Sandow SL, Sadananda P, Burcher E, Moore KH, Porcine bladder and urothelial, myofibroblast and detrusor muscle cells: characterisation and ATP release. Frontiers in Pharmacology 2011; 2: 27-3. DOI: 10.3389/fphar.2011.00027
  88. Indraratna P, Walsh CA, Moore KH. Intra-operative cystoscopy in gynaecological surgery.  ANZJOG 2011; 51: 272-5. DOI: 10.1111/j.1479-828X.2010.01277.x
  89. Walsh CA, Allen W, Parkin K, Mukerjee C, Moore KH. “Low-count” bacteriuria in refractory idiopathic detrusor overactivity versus controls. Urogynaecologia 2011; 25: e4 11-15. DOI: 10.4081/uij.2011.e4
  90. Walsh CA, Siddins A, Parkin K, Mukerjee C, Moore KH. Prevalence of “low count’ bacteriuria in female urinary incontinence versus continent female controls: a cross-sectional study. Int. Urogynaecol J, 2011; 22: 267-272. DOI: 10.1007/s00192-011-1506-0
  91. Shahab RB, Sarma S, Moore KH, Kuteesa WMA, Cebola M, Walsh CA, Wang YA, Karantanis E. Randomized Controlled Trial of Cough Test versus no Cough Test in the Tension-Free Vaginal Tape Procedure effect upon Voiding Dysfunction & 12 month Efficacy. Int Urogynecol J, 2012; 23: 435-441. DOI: 10.1007/s00192-011-1594-x
  92. Karantanis E, Painter V, Moore KH. Does patient activity level affect 24-hour pad test results in stress-incontinent women? Neurol & Urodyn 2012; 31: 143-147. DOI: 10.1002/nau.21169
  93. Ho M, Kuteesa W, Short A, Eastwood A, Moore KH. Incontinence after childbirth: Long-term analysis of direct costs of conservative and surgical therapy. ANZ Cont J 2012; 18: 10-19
  94. Hannan TJ, Totsiks M,  Mansfield KJ, Moore KH, Schembri MA, Hultgren SJ. Host-Pathogen Checkpoints and Population Bottlenecks in Persistent and Intracellular Uropathogenic E Coli Urinary Tract Infection. FEMS Microbiol Rev. 2012 36: 616-48. DOI: 10.1111/j.1574-  6976.2012.00339.x
  95. Walsh CA, Cheng Y, Mansfield KJ, Parkin K, Mukerjee C, Moore KH. Decreased intravesical ATP in patients with refractory detrusor overactivity and bacteriuria.  J Urol 2013; 189: 1383-7. DOI: 10.1016/j.juro.2012.10.003
  96. Cheng Y, Mansfield KJ, Allen W, Millard RJ, Burcher E, Moore KH. Correlation between Cystome tric volumes, ATP release, and pH in women with overactive bladder versus controls.Neurourol Urodyn. 2013; 32: 969-73. DOI: 10.1002/nau.22344
  97. Davidson JE, Moore KH. Is Pelvic Floor Muscle Training as Effective for Urinary Incontinence in the Elderly as Compared to the General Population? ANZ Cont J 2013: 19: 18-25 Invited Review.
  98. Mansfield KJ, Cowan T, Cheng Y, Allen W, Moore KH. Predicting refractory Detrusor overactivity: Are there any clues at Diagnosis? EMJ Urology 2013; 1: 87-91. DOI: 10.33590/emjurol/10313660
  99. Moore KH, Allen W, Woodman J, Bushati A, Burcher E. Response to resiniferatoxin in women with refractory detrusor overactivity: Role of bacterial cystitis. Aust NZ Cont J 2013; 19: 66-73.
  100. Deepak I, Sundac L, Benjamin W, Moore KH, Ulett G. Asymptomatic bacteriuria: prevalence rates of casual microbes, etiology of infection in different patient populations, and recent advances in molecular detection. FEMS Microbiol Lett. 2013; 346: 1-10. DOI: 10.1111/1574-6968.12204
  101. Wong V, Moore KH. Female urinary incontinence. Medical Observer 2013; 25-27. Invited Review.
  102. Wong V, Kim S, Moore KH. Why are some women with pelvic floor dysfunction unable to contract their pelvic floor muscles? ANZJOG 2013; 54: 198-205 Oct 1. doi: 10.1111/ajo.12133.
  103. Chen Z; Wong V, Wang A, Moore KH. Nine year objective and subjective follow up of the Ultra-Lateral anterior repair for cystocele. Int. Urogyn J, 2013; 25: (3) 387-392. DOI: 10.1007/s00192-013-2234-4
  104. Bahadory F, Moore KH; Liu Lu; Burcher E. Gene expression and functional role of muscarinic, tachykinin and purinergic receptor. Frontiers in Pharmacology 2013; 4:1 DOI:10.3389/fphar.2013.00148
  105. Hagen S, Stark D, Glazener C, Dickson S, Barry S, Elders A, Frawley H, Galea MP, Logan J, McDonald A, McPherson G, Moore KH, Norrie J, Walker A, Wilson D, Individualised Pelvic Floor muscle training in women with pelvic organ prolapse: a multicentre randomised controlled trial. Lancet 2014; 383: 796-806. DOI: 10.1016/S0140-6736(13)61977-7
  106. Lim V, Khoo J, Wong V, Moore KH. Recent studies of genetic dysfunction in pelvic organ prolapse: the role of collagen defects. Aust NZ J & Gynaecol 2014; 54: 198–205; DOI: 10.1111/ajo.12169
  107. Moore KH, Malykhina AP. What is the role of Covert Infection in Detrusor Overactivity, and other LUTD? ICI-RS Neurourol & Urodyn 2014; 33: 606-610. Invited Review. DOI:10.1002/nau.22589
  108. Karantanis E, Stanton S, Parsons M, Robinson D, Blackwell AL, Cardozo, Moore KH. Women’s preferences for treatment for stress incontinence – physiotherapy or surgery. ANZ Cont J .2014; 20(2): 34-40. ISSN: 1448-0131. DOI: 10.1002/nau.22589
  109. Cheng Y, Mansfield KJ, Allen W, Chess Williams R, Moore KH. ATP During Early Bladder Stretch is important for Urgency in Detrusor Overactivity Patients. BioMed Research Int J 2014: DOI: 10.1155/2014/204604
  110. Bishop G, Moore KH. Painful bladder syndrome. Medicine Today; 2014; 15: 401-406 Invited Review. ISSN: 1443430X
  111. te West NID, Moore KH. Recent Developments in the non-surgical Management of Pelvic Organ Prolapse. Invited Rev 2014: Curr Obstet Gynecol Rep 3:172-179. DOI: 10.1007/s13669-014-0087-6
  112. Cheng Y, Moore KH. Study of Oestrodiol Effect Upon ATP release in Primary Pig Urothelium Cell Culture: A Possible Mechanism of Action for Topical Vaginal Oestradiol? Neurourol & Urodyn 2014; 33: 809-810. ISSN: 0733-2467
  113. Bahadory F, Mansfield KJ, Moore KH, Burcher E, Liu L. Gene Expression of Onabotulinum Toxin A Target Proteins in Porcine Bladder: Possible effect on substance P Release? Neurourol & Urodyn 2014; 33: 719-720. ISSN: 0733-2467
  114. te West NID, Moore KH. Urinary Tract Infection in Gynaecology and Obstetrics. Obstetrics, Gynaecology & Reproductive Medicine, 2014; 24: 321-325. DOI: 10.1016/j.ogrm.2014.08.002 
  115. te West NID, Parkins K, Hayes W, Costa D, Kasparian N, Moore KH. Does motivation predict outcome of Pelvic Floor Muscle retraining? Neurourol & Urodyn 2015 DOI: 10.1012/nau22917
  116. McKenna JB, Parkin K, Cheng Y, Moore, KM. Objective Efficacy of the TVT in Obese versus Non-Obese Women at Median 5 year Follow up. ANZ Cont J 2016; 22: 25-30. DOI:  10.1111/ajo.12516 
  117. Wong V, Rodirgo Guznian R, Sheu KL, Chow D, Moore KH, Dietz P. Laparoscopic Sacrocolpopexy: How low does the mesh go? US Obstets Gynae 2016; DOI: 10.1002/uog.15882
  118. Weber M, Lim V, Oryszczyn J, te West NID, Souget J, Jeffery S, Roovers JP, Moore KH. The Effect of Vaginal Oestriol on Subjective and Objective Symptoms of Stress Urinary Incontinence and Vaginal Atrophy: An International Multi-Centre Pilot study. Gynecol & Obstet Invest. 2016 DOI: 10.1159/ 000445074
  119. A Budden , te West NID, Sturgess A, Moore KH. Pelvic Floor Dysfunction in Female Sjogren’s Syndrome: An 8 Year Audit. Int Urogyn J. 2016; DOI: 10.1007/s00192-016-2985-9
  120. Cheng Y, Chen Z, Gawthorne JA, Mukerjee C, Varettas K,Mansfield KJ, Schembri MA, Moore KH Detection of intracellular bacteria in exfoliated urothelial cells from women with urge incontinence Pathogens and Disease 2016 DOI: 10.1093 FEMS Pathogens and Disease  2016 Vol. 74 (7). DOI: 10.1093/femspd/ftw067
  121. Woodman J, Cowan T, Karantanis E, Moore KH. A Longitudinal study of asymptomatic rectocele. ANZ Cont J. 2016; 22(2): 26-30. ISSN: 1448-0131
  122. Hafiz Sana-Ur-Rehman, Markus I, Moore KH. Mansfield KJ, and Lu Liu “Expression and localization of pannexin-1 and CALHM1 in porcine bladder and their involvement in modulating ATP release” American Journal of Physiology – Regulatory, Integrative and Comparative Physiology 2017; Hide license312: R763-R772. DOI: 10.1152/ajpregu.00039.2016 
  123. Foust-Wright C; Wissig S, Stowell C, Olsen E, Anderson A, Anger J, Cardozo L, Cotterill N, Gormley EA, Toozs-Hobson P, Heesakkers J, Herbison P, Moore KH, McKinney J, Morse A, Pulliam S, Szonyi G, Wagg A, Milsom I.  Development of a core set of outcomes measures for OAB treatment  Int. Urogyn J, 2017; DOI 10.1007/s00192-017-3481-6
  124. Patton V, Parkin K, Moore KH, Lubowski D. A prospective “bottom up”study of the costs of faecal incontinence in ambulatory patients. Neurourol & Urodyn, 2018: 37: 1672-1677 DOI: 10.1002/nau.23450 
  125. Chen Z, Phan MD, Bates L, Peters KM, Mukerjee M, Moore KH, Schembri M. The Urinary microbiome in patients with refractory urge incontinence and recurrent urinary tract infection. Int J Urogynae 2018 29:1775-1782 DOI: 10. 10.1007/s00192-018—3679-2
  126. Ladanchuk T, Kwak S, Bates LJ, Parkin K, Harris K, Fitzgerald O, Lynch W, Moore KH. Vascular measures of atherosclerosis in detrusor overactivity and controls. Neurourol & Urodyn: 2018 DOI: 10.1002/nau.23784
  127. Grundy L, Chess-Williams R, Brierley S, Mills K, Moore KH, Mansfield KJ, Rose’Meyer R, Sellers D, Grundy D.  “NKA enhances bladder afferent mechanosensitivity via urothelial and detrusor activation” Am J Physiol 2018 DOI: 10.1152/ajprenal.00106.2018 
  128. Chen Z, Bates L, te West N, Moore KH. A Nine year audit of the efficacy of diathermy for cystistis Cystica. Urogynaecologia  2019;31:223-226. DOI: 10.4081/uij.2019.223
  129. Leek H, Reus A, Mansfield KJ, Stephenson Z, Moore KH. Clean Intermittent Self-Catherisation: a Randomised controlled crossover trial of single-use versus multiple re-use of catheters, in relation to bacterial cystitis and patients’ costs. ANZ Cont J , 2019; 25: 64-73
  130. Brierley SM, Goh KGK, Sullivan MJ, Moore KH, Ulett GC, Grundy L. Innate immune response to bacterial urinary tract infection sensitises high-threshold afferents and recruits silent nociceptors. PAIN, 2020; 161(1), p202-210. DOI: 10.1097/j.pain.0000000000001692.
  131. te West NID, Day R, Hiley B, White C, Wright M, Moore KH. Estriol serum levels in new and chronic users of vaginal estriol cream: a prospective observational study. Neurourol & Urodyn, 2020; 0-0. DOI: 10.1002/nau.24331.
  132. te West NID, Day RO, Graham GG, Wright M, White CP, Moore KH. Serum concentrations of estriol vary widely after application of vaginal estriol cream. Brit J Clin Pharmacol 2020. DOI: 10.1111/bcp.14635
  133. Chen Z, Moore KH, Mansfield KJ, Ognenovska S, Allen W, Parkin K, Mukerjee C, Aryal NR, Gebski V. Effect of antibiotics on urine leakage in women with refractory Detrusor Overactivity: a Phase IIb randomised trial. Neurourol & Urodyn 2020. DOI: 10.1002/nau.24525
  134. Chen Z, Ognenovska S, Sluyter R, Moore KH, Mansfield KJ. Urinary cytokines in women with refractory Detrusor Overactivity: a longitudinal study of rotating antibiotic versus placebo treatment. PLoS One 2021. doi.org/10.1371/journal.pone.0247861
  135. Ognenovska S, Chen Z, Mukerjee C, Moore KH, Mansfield KJ. Bacterial colonization of bladder urothelial cells in women with refractory Detrusor Overactivity: the effects of antibiotic therapy Pathog Dis. 2021 Jul 2 doi: 10.1093/femspd/ftab031
  136. Keane J, Young N, Goh J, Atherton M, Yin J, Moore KH, Hall P, Higgs P, Leitch A, Lee J, Rosamilia A. A comparison of two intravesical bladder instillations for Interstitial Cystitis/Bladder Pain Syndrome. Eur J Obs & Gynae. 2021; 25:230-234  doi.org/10.1016/J.EJOGRB.2020.10.060
  137. Bower W, Rose G, Whishaw M, Ervin C, Wang C, Moore KH. The association between nocturia, hormonal symptoms and bladder parameters in women: an observational study. BJOG 2021. DOI: 10.1111/1471-0528.16752
  138. Moore KH, Allen W, Beaupert F, Parkin K, Chan C, Chen Z. Efficacy and patient acceptability of the Continence Dish Int Urogyn J 2021 org/10.1007/s00192-021-04969-7
  139. Taidi Z, Zhou T, Moore KH, Mansfield KJ, Liu Lu; P2X7 Receptor Blockade Protects Against Acrolein-Induced Bladder Damage: A Potential New Therapeutic Approach for the Treatment of Bladder Inflammatory Diseases. Front. Pharmacol 682520 (2021). doi:10.3389/fphar.2021.682520. Published 12 Aug 2021. Impact Factor: 5.810
  140. Manoharan A, Ognenovska S, Paino D, Whiteley G, Glasbey T, Kriel FH, Farrell J, Moore KH, Manos J, Das T. N-Acetylcysteine Protects Bladder Epithelial Cells from Bacterial Invasion             and Displays Antibiofilm Activity against Urinary Tract Bacterial Pathogens.  Antibiotics (Basel). 2021  doi: 10.3390/antibiotics10080900
  141. Mansfield KJ, Chen Z, Moore KH, Grundy L Urinary Tract Infection in Overactive Bladder: An update on pathophysiological mechanisms Front Physiol 2022: 13: 886782. Doi 10.3389/phys.2022.886782
  142. 139. Moore KH, Lammers K, Allen W, Parkin K, te West NID. Does monthly self management of vaginal ring pessaries reduce the rate of adverse events? Eur J Obs & Gynae & Repro Biol 2022 doi: 10.1016/j.eurox.2022.100164
  143. Taidi Z, Mansfield KJ, Hafiz Sana-Ur-Rehman, Moore KH, Liu Lu;  Protective effect of Purinergic P2X7 Receptor Inhibition on Acrolein-Induced Urothelial Cell Damage; Front Physiol 2022 (IF 4.566) DOI: 10.3389/fphys.2022.885545
  144. Ognenovska S, Mukerjee C, Sanderson-Smith M, Schembri M, Moore KH, Mansfield KJ, Virulence mechanisms of common uropathogens and their intracellular localisation within urothelial cells  Pathogens and diseases, 2022 DOI: 10.3390/pathogens11080926
  145. te West NID, Harris K, Jeffrey S, de Nie I, Parkin K, Roovers JP, Moore KH. The effect of 12 weeks of estriol cream on stress urinary incontinence post‐menopause: a prospective multinational observational study. Neurourol Urodyn. 2023;1‐8 DOI: 10.1002/nau.251658
  146. Manoharan A, Farrell J, Aldilla VR, Whiteley G, Kriel E, Glasbey T, Moore KH, Kumar N, Manos J, Das T. Disarming Proteus mirabilis and blowing its cover: N-acetylcysteine suppresses P. mirabilis urease activity, prevents biofilm formation, and catheter encrustation. Biofilms and Microbiomes, 2023 (NPJBIOFILMS-02028).
  147. Konesan J, Wang J, Moore KH, Mansfield KJ, Liu L, Cranberry, but not D-mannose and ibuprofen, prevents against uropathogenic Escherichia coli- induced cell damage and cell death in MDCK cells Frontiers in Microbiology 2023 14.1319785. DOI 10.3389/fmicb.2023.1319785
  148. Young R, Moore KH. The Painful Bladder, Aust N Z J Obstets Gynaecol, 2023: 25-28
  149. Moore KH, Ognenovska S, Chua Xin-Yi, Chen Z, Hicks C, El Assaad F, Te West, N, El-Omar E. Change in microbiota profile after vaginal oestriol cream in postmenopausal women with stress incontinence. Frontiers in Microbiology   15:1302819. doi: 10.3389/fmicb.2024.1302819
  150. Manoharan A, Farrell J. ,Aldilla VR,  Whiteley G,  Kriel E, Glasbey T,  Kumar N,  Moore KH,  Manos J, Das T.  N-acetylcysteine  prevents catheter biofilm obstruction and inflammation by uropathogenic Pseudomonas aeruginosa Revisions underway   September 2024. BIOFLM-D-23-00125.
  151. Te West, N, Harris K, Chapman C, Moore, KH. Does Urodynamic stress incontinence increase after the menopause? Results from 2994 urodynamic studies in Australian women. International Urogynecology Journal doi: 10.1007/s00192-2024-05876-
  152. KH Moore A Review: Patient questions about use of vaginal ring pessaries for prolapse. Gynecology and Pelvic Medicine, accepted Sept 2024.
  153. Konesan J, Moore KH, Mansfield K, Liu L, Uropathogenic Escherichia coli causes significant urothelial damage in an ex vivo porcine bladder model, with no protective effect observed from cranberry Minor Revisions underway, Pathogens and Disease, August 2024
  154. Mansfield KJ, Chen Z, Ognenovska S, Briggs N, Sluyter R, Moore KH. A cross sectional study of cytokines in women with refractory Detrusor Overactivity versus controls, submitted International Urogynaecology Journal August 2024.
  1. Jayasinghe RT, Ruseckaite R, Dean J, Kartik A, Wickremasinghe AC, Daly O, O’Connell HE Craig A, Duggan A, Vasiliadis D, Karantanis E, Gallagher E, Holme G, Keck J, Williams J, King J, Yin J, Short J, Sketcher-Baker K, Brennan P, Rayner S, Ahern.,Establishment and initial implementation of the Australasian Pelvic Floor Procedure Registry. Int Urogynecol J. 2023 Aug;34(8):1697-1704.
  2. Nagi K, Karantanis E, Mallitt KA. Do doctors preferring forceps encounter more obstetric anal sphincter injuries: A retrospective analysis. Aust N Z J Obstet Gynaecol. 2023 Apr: 63 (2): 187-192.
  3. Everist R, Burrell M, Parkin K, Patton V, Karantanis E. The long-term prevalence of anal incontinence in women with and without obstetric anal sphincter injuries. Continence 2023 Mar (5): 1-6.
  4. Everist R, Burrell M, Mallitt K, Parkin K, Patton V, Karantanis E. Postpartum Anal Incontinence in Women with and without Obstetric Anal Sphincter Injuries. In Urogynaecol J 2020 Mar 10.
  5. Rickard-Bell A, Malouf D, Karantanis E. What not to expect when you’re expecting – Postpartum Proximal Ureteric Rupture, a Case Report. Case Rep Womens Health. 2020 Mar 3;26
  6. Alexander JW, Karantanis E, Turner RM, Faasse K, Watt C. Patient attitude and acceptance towards episiotomy during before and after information provision: A questionnaire. IUJ 2020 Mar: 31 (3): 521-528.
  7. V Patton, S Kumar, K Parkin, E Karantanis, PG Dinning. The Relationship Between Residual Sphincter Damage After Primary Repair, Faecal Incontinence, and Anal Sphincter Function in Primiparous Women With an Obstetric Anal Sphincter Injury. Neurourol Urodyn. 2019 Jan;38(1):193-199
  8. Bates LJ, Melon J, Turner R, Chan SSC, Karantanis E. Prospective comparison of obstetric anal sphincter injury incidence between an Asian and Western hospital. Int Urogynecol J. 2018 Apr 13.
  9. Burrell M, Dilgir S, Patton V, Parkin K, Karantanis E. Risk factors for obstetric anal sphincter injuries and postpartum anal and urinary incontinence: a case-control trial. Int Urogynecol J. 2015 Mar 26:3
  10. Gendy R, Walsh CA, Walsh SR, Karantanis E. Vaginal hysterectomy versus total laparoscopic hysterectomy for benign disease: a meta-analysis of randomized controlled trials.. Am J Obstet Gynecol. 2011 May;204(5):388.
  11. Karantanis E, Fynes MM, Stanton SL. The tension-free vaginal tape in older women. BJOG. 2004 Aug;111(8):837-41
  12. Karantanis E, MM Fynes, Meen-Yau Thum, Martin Bircher, SL Stanton: Case Report-Ruptured urogenital diaphragm associated with spontaneous vaginal delivery. BJOG. 2003 Jun;110(6):630-2.
  13. Karantanis E, D. Alcock, L. Phelan, C. Homer, GK. Davis. Introducing external cephalic version to clinical practice. ANZJOG. 2001;41  (4) . Nov 2001